GlassScriptPhysician profile
Shadi V Barbu
NPI 1841678802
$7,800.58
in general payments reported to CMS, 2019-2025
20 companies · $2,003 in 2025
The $2,003 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2021: $24.52 · 2022: $2,103 · 2023: $1,543 · 2024: $698 · 2025: $2,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339 · Travel and Lodging: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,338.89 |
| Travel and Lodging | $1,904.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,384.68 | 2022-2025 | Percept PC Brainsense, Sensight |
| Medtronic USA, INC. | $1,327.57 | 2019 | |
| Boston Scientific Corporation | $1,127.27 | 2022-2025 | General - Dbs, Vercise |
| Amneal Pharmaceuticals LLC | $446.59 | 2022-2025 | Rytary, Crexont |
| Abbvie INC. | $300.82 | 2022-2025 | Duopa, Ubrelvy, Botox |
| Revance Therapeutics, INC. | $286.95 | 2024 | Daxxify |
| Teva Pharmaceuticals USA, INC. | $186.02 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $140.81 | 2019-2025 | Nuplazid |
| Kyowa Kirin, INC. | $109.67 | 2021-2024 | Nourianz |
| Biogen, INC. | $87.22 | 2023-2025 | Skyclarys, Skyclarys |
| Mdd US Operations, LLC | $85.97 | 2023-2025 | Apokyn |
| Neurocrine Biosciences, INC. | $84.08 | 2024-2025 | Ingrezza |
| Merz Pharmaceuticals, LLC | $56.45 | 2023-2025 | Xeomin, Ampyra, Inbrija |
| Acorda Therapeutics, INC | $38.54 | 2022-2024 | Inbrija |
| Averitas Pharma INC. | $35.76 | 2025 | Qutenza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $30.44 | 2022-2023 | |
| Ge Healthcare | $23.78 | 2023 | |
| Avion Pharmaceuticals | $17.29 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.58 | 2024 | Dysport |
| Ucb, INC. | $15.09 | 2023 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadi Barbu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.